Lantheus Holdings (LNTH) Gains from Sales and Divestitures (2016 - 2025)
Lantheus Holdings (LNTH) reported Gains from Sales and Divestitures of $622533.0 for Q4 2025, up 190.71% quarter-over-quarter from $214142.0 in Q4 2016.
Lantheus Holdings (LNTH) Gains from Sales and Divestitures (2016 - 2025) Analysis & Trends
Lantheus Holdings (LNTH) has 2 years of Gains from Sales and Divestitures data on file, last reported at $622533.0 in Q4 2025.
- Gains from Sales and Divestitures for Q4 2025 came in at $622533.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $622533.0 (changed N/A YoY), and the FY2025 annual result was $622533.0, changed N/A from the prior year.
- Gains from Sales and Divestitures climbed to $622533.0 in Q4 2025 per LNTH's latest filing, from $214142.0 in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $622533.0 in Q4 2025 and troughed at $622533.0 in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Liquidia | 5.64 Bn | 5.42 Bn | 121.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 622,533.00 |
| Dec 31, 2025 | 622,533.00 |
| Dec 31, 2016 | 214,142.00 |
| Dec 31, 2016 | 214,142.00 |